Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Purple Biotech ( (PPBT) ) has provided an announcement.
On January 7, 2026, Purple Biotech reported that its tri-specific antibody IM1240, from the CAPTN-3 platform, successfully completed a non-human primate toxicology study, showing dosing tolerance up to 300 times higher than a non-capped comparator with markedly reduced immune-related toxicity and minimal cytokine release. The study also demonstrated a favorable pharmacokinetic profile, including increased systemic exposure and prolonged half-life attributed to IM1240’s capping design and albumin moiety, reinforcing the potential for an expanded therapeutic window and supporting its progression toward first-in-human clinical development with further advanced toxicological assessments planned.
The most recent analyst rating on (PPBT) stock is a Hold with a $0.65 price target. To see the full list of analyst forecasts on Purple Biotech stock, see the PPBT Stock Forecast page.
Spark’s Take on PPBT Stock
According to Spark, TipRanks’ AI Analyst, PPBT is a Neutral.
The score is held down primarily by the lack of revenue, ongoing losses, and negative free cash flow, indicating continued reliance on external funding. Technical indicators also point to a bearish trend with weak momentum. The main positive is the low-debt balance sheet, which reduces near-term leverage risk but does not offset weak operating fundamentals.
To see Spark’s full report on PPBT stock, click here.
More about Purple Biotech
Purple Biotech Ltd. (NASDAQ/TASE: PPBT) is a Rehovot, Israel-based clinical-stage oncology company developing first-in-class immunotherapies to overcome tumor immune evasion and drug resistance. Its lead CAPTN-3 platform comprises capped tri-specific antibodies that target tumor-associated antigens while engaging both T cells and NK cells, with lead candidates IM1240, targeting 5T4, advancing toward the clinic and IM1305, targeting TROP2, in preclinical development; the pipeline also includes CM24, a CEACAM1-blocking antibody that has shown improved outcomes in a Phase 2 pancreatic cancer study, and NT219, a dual IRS1/2 and STAT3 inhibitor in a Phase 2 head and neck cancer trial.
Average Trading Volume: 7,398,604
Technical Sentiment Signal: Sell
Current Market Cap: $6.45M
For detailed information about PPBT stock, go to TipRanks’ Stock Analysis page.